TGF‐β treatment reversed the decreases in the proliferation, invasion and migration of tumor cells induced by SCRN1 knockdown as well as the decrease in p-SMad3 expression in OSCC cell lines, suggesting that SCRN1 acts promotes OSCC by modulating the TGF‐β/Smad3 pathway. Here, SCRN1 is linked to neoplasm.